UNSPSC 51422437: Tixocortol pivalate

This classification denotes a hydrocortisone analog and 21-thiol hydrocortisone derivative C26H38O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K28E35M3B, chemically known as pregn-4-ene-3,20-dione, 21-((2,2-dimethyl-1-oxopropyl)thio)-11,17-dihydroxy-, (11.beta.)-, but more generally known as tixocortol pivalate, which bears US NIH Compound Identifier 15052414. European Medicines Agency schedules Tixocortol pivalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04894MIG.

Most nations, for tariff and trade purposes, schedule tixocortol pivalate under HS 29372900 and SITC 54153. As of Q4 2014, TIXOCORTOL PIVALATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CSC(=O)C(C)(C)C)O)C)O.

UNSPSC 51422437 Tixocortol pivalate is a Commodity code that in practice covers pharmaceutical products and related health-supply procurement, though the recent opportunities tagged under it do not align cleanly with the code's nominal scope. State and local health departments and public-health agencies source these items through competitive bidding processes. The work involves purchasing pharmaceutical products, naloxone and drug deactivation systems, and related health commodities for community health initiatives and pharmacy benefit programs, with vendors responsible for meeting supply schedules, maintaining required certifications, and complying with federal regulations tied to potential FEMA or state funding.

Activity under the code appears concentrated in Florida and Texas. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities around a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with a response deadline of April 3, 2026. The mismatch between the code name (tixocortol pivalate, a specific corticosteroid) and the actual work being solicited (naloxone, drug deactivation systems, and pharmacy benefit management) signals that this code may carry inconsistent tagging at the state and local level or that opportunities are being filed under an incorrect UNSPSC designation.